ORGO · Organogenesis Holdings Inc.
$1.71
-0.09 (-4.75%)
At close · Aug 17
Market Cap
$230.33M
Shares
128.67M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.79
Open$1.76
Day$1.72–1.81
52W close$1.76–6.54
Avg vol 30d884K
Short int13.3M · 10.3% float · 20.8d
Short vol50%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−47%
below
Price vs 50-day avg
−24%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−32%
trailing
6-month return
−54%
trailing
YTD return
−65%
this year
Relative strength
−68%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.35% of float · ▲ +1.4% MoM · 20.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
133 holders — mid 3-yr range
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
Gross margin
65%
contracting
EPS growth
+1600%
Y/Y
Free cash flow
$-24.5M
Balance sheet
$44.0M
net cash
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
9.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
year ending December 31, 2026
Total net revenue
Initiated
$179M – $215M
prior FY $564.17M
midpoint −65.1% Y/Y
second half of 2026
Second half revenue decline (year over year)
Initiated
64% – 74%
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2024
Net revenue
· 12 months ended December 31, 2024
$445M – $470M
Advanced Wound Care net revenue
· 12 months ended December 31, 2024
$415M – $435M
Adjusted EBITDA
· 12 months ended December 31, 2024
$15.8M – $35M
Surgical & Sports Medicine net revenue
· 12 months ended December 31, 2024
$30M – $35M
Revenue
· second quarter 2024
$120M – $125M
Guided vs delivered
· last 2 settled
Net revenue
12 months ended December 31, 2024
guided $445M – $470M
$482.04M
Beat +5.4%
Revenue
second quarter 2024
guided $120M – $125M
$130.23M
Beat +6.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−47%
Bearish
Price vs 50-day avg
−24%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.35% of float · ▲ +1.4% MoM · 20.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
133 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 1%
Range high $7
vs 200-day avg -47%
vs 50-day avg -24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | $82.5M | six months ended June 30, 2026 | — |
|
|
|||
| Adjusted net loss non-GAAP | $132.8M | six months ended June 30, 2026 | — |
|
|
|||
| Non-GAAP operating loss non-GAAP | $97.1M | six months ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $98.1M | FY2025 | — |
| Adjusted net income non-GAAP | $55.2M | FY2025 | — |
| Non-GAAP operating income non-GAAP | $69.6M | FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ORGO
this stock
Organogenesis Holdings Inc.
|
$230.33M | -65.4% | +17.0% | — | 10.3% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ORGO | -3.8% | -31.7% | -54.3% | -24.5% | -65.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -4.2% | -36.1% | -68.1% | -28.4% | -79.3% |
Key facts
CIK
1661181
CUSIP
68621F102
13F (30d)
126 filings
126 filers
Visit website
Investor relations